I
321.36
0.36 (0.11%)
| Previous Close | 321.00 |
| Open | 319.00 |
| Volume | 615,511 |
| Avg. Volume (3M) | 911,733 |
| Market Cap | 22,615,674,880 |
| Price / Earnings (TTM) | 57.80 |
| Price / Earnings (Forward) | 59.52 |
| Price / Sales | 10.48 |
| Price / Book | 16.45 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | 18.29% |
| Operating Margin (TTM) | 15.61% |
| Diluted EPS (TTM) | 5.54 |
| Quarterly Revenue Growth (YOY) | 28.80% |
| Quarterly Earnings Growth (YOY) | -31.30% |
| Total Debt/Equity (MRQ) | 131.40% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | 406.50 M |
| Levered Free Cash Flow (TTM) | 84.25 M |
| Return on Assets (TTM) | 6.94% |
| Return on Equity (TTM) | 37.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Insulet Corporation | Bearish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 102.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 365.00 (Oppenheimer, 13.58%) | Buy |
| Median | 350.00 (8.91%) | |
| Low | 300.00 (Barclays, -6.65%) | Hold |
| Average | 343.60 (6.92%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 319.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 08 Sep 2025 | 365.00 (13.58%) | Buy | 349.56 |
| Barclays | 21 Aug 2025 | 300.00 (-6.65%) | Hold | 327.85 |
| Canaccord Genuity | 08 Aug 2025 | 353.00 (9.85%) | Buy | 307.10 |
| RBC Capital | 08 Aug 2025 | 350.00 (8.91%) | Buy | 307.10 |
| Wells Fargo | 08 Aug 2025 | 350.00 (8.91%) | Buy | 307.10 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COUSIN LAETITIA | - | 349.56 | -797 | -278,599 |
| SINGH PREM | - | 349.56 | -687 | -240,148 |
| Aggregate Net Quantity | -1,484 | |||
| Aggregate Net Value ($) | -518,747 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 349.56 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COUSIN LAETITIA | Officer | 08 Sep 2025 | Sell (-) | 797 | 349.56 | 278,599 |
| COUSIN LAETITIA | Officer | 08 Sep 2025 | Option execute | 797 | - | - |
| SINGH PREM | Officer | 08 Sep 2025 | Sell (-) | 687 | 349.56 | 240,148 |
| Date | Type | Details |
|---|---|---|
| 16 Sep 2025 | Announcement | Insulet Announces CFO Transition |
| 25 Aug 2025 | Announcement | Insulet Elevates Eric Benjamin to Chief Operating Officer |
| 19 Aug 2025 | Announcement | Insulet to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency¹) |
| 08 Jul 2025 | Announcement | Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025 |
| 19 Jun 2025 | Announcement | Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |